University of Minnesota Medical School researchers have begun enrolling patients in newly launched clinical trials involving a blood pressure medication, losartan, as a potential treatment for those recently diagnosed with COVID-19.

Bruce Walcheck, PhD, describes how membership in the Medical School’s Stem Cell Institute led to today’s first-ever, FDA-approved clinical trial using genetically-engineered, induced pluripotent stem cells (iPSC) to treat various cancers.

Subbaya Subramanian, MS, PhD, explains new findings where he and his team compared administering different combinations and timings for chemotherapy and immunotherapy treatments for cancer patients and new best practices for the surgical removal of tumor-draining lymph nodes.

Kathryn Cullen, MD, and her colleagues began a study called, “BRIDGES,” which looks to better understand adolescent brain development in youth with self-harm behaviors.

An interdisciplinary team of researchers from the University of Minnesota recently refined and expanded a laboratory-developed procedure that tests for COVID-19, using more readily available reagents to mitigate the impact of the testing supply shortage and increase daily testing volumes.

The University of Minnesota has developed a COVID-19 antibody test that will be available first to frontline health care workers in M Health Fairview’s Bethesda hospital.

A group of University of Minnesota faculty are developing two masks with special filtration material that may be able to support local PPE demands.

Jeffrey Wozniak, PhD, LP, and his team created a choline-based vitamin treatment to help increase brain development in children with fetal alcohol spectrum disorders (FASD), which are brain abnormalities as a result of prenatal alcohol exposure.

More Candida (fungi) species have become resistant to available antifungal medications, which makes treating fungal infections in patients increasingly difficult.

A clinical trial led by the University of Minnesota on a post-exposure treatment for the coronavirus (COVID-19) is expanding participant enrollment opportunities.